Compare DexCom, Inc. (DXCM) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs SAP SE — how do they compare? DexCom, Inc. trades at $89.34 (market cap $33.79B), while SAP SE trades at $203.58 (market cap $240.81B). The key difference: SAP SE is far larger — about 7.1× DexCom, Inc.'s market cap, and SAP SE pays a 1.4% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SAP | |
|---|---|---|
Market Cap | $33.79B | $240.81B |
Sector | Health | Technology |
52-Week High | $89.53 | $280.46 |
52-Week Low | $54.84 | $146.38 |
Enterprise Value | $33.24B | $239.52B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
SAP trades at $208.55, up 1.16% today, near its consensus price target of $209.67. The stock shows a bullish technical trend with strong moving averages, though oscillators indicate overbought conditions. Recent Q2 2026 earnings missed EPS estimates but revenue grew, driven by cloud demand. The company maintains robust profitability with a net income margin of 20.41% and solid cash flow from operations of $9.16B in 2025.
Outlook is mixed: AI and cloud growth offer upside, but profit guidance cuts and execution risks pose challenges. Analysts are generally bullish (53.49% buy ratings), yet investors should weigh high valuation multiples against competitive pressures in enterprise software. Near-term resistance lies at $211.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
